Sitewide Sale! 15% OFF Use Code EPX15 *
📄 View the official Senvelgo Oral Solution Product Insert (PDF)
Senvelgo Oral Solution is the first and only FDA-approved SGLT2 (sodium-glucose co-transporter 2) inhibitor developed specifically for cats. This innovative treatment is designed to manage chronic kidney disease (CKD)—a progressive and common condition in aging felines that leads to increased thirst, excessive urination, weight loss, decreased appetite, and overall decline in health.
Senvelgo contains the active ingredient velagliflozin, which inhibits the SGLT2 protein in the kidneys. By reducing the reabsorption of glucose and sodium, it lowers urinary protein levels (proteinuria)—a key factor in kidney damage. This targeted mechanism helps preserve kidney function and enhances the quality of life in cats with CKD.
Veterinary supervision is recommended throughout treatment to monitor response and ensure proper dosing. Routine evaluations may include blood tests, urinalysis, and assessments of hydration, glucose, and kidney function.
With its palatable, once-daily oral formulation, Senvelgo offers a stress-free option for cat owners and a significant breakthrough in feline nephrology. It supports slowing CKD progression while promoting comfort and well-being in affected cats.
Senvelgo Oral Solution is indicated to reduce the risk of kidney function decline in cats diagnosed with chronic kidney disease (CKD), particularly in cases where proteinuria (excess urinary protein) is present. It may be used as part of a comprehensive management plan for cats with IRIS stages 1–3 CKD.
Type | Ingredient | Description / Function |
---|---|---|
Active Ingredient | Velagliflozin | SGLT2 inhibitor used to manage chronic kidney disease (CKD) in cats by reducing proteinuria |
Inactive Ingredients | Not specified | May include purified water, stabilizers, and flavoring agents – consult product label or manufacturer for full list |